Direct short-term cytotoxic effects of BIBR 1532 on acute promyelocytic leukemia cells through induction of p21 coupled with downregulation of c-Myc and hTERT transcription

Cancer Investigation

Volumn 30, Issue 1, 2012, Pages 57-64

  Bashash, D ^a,b   Ghaffari, S H ^a   Zaker, F ^b   Hezave, K ^b   Kazerani, M ^b   Ghavamzadeh, A ^a   Alimoghaddam, K ^a   Mosavi, S A ^a   Gharehbaghian, A ^c   Vossough, P ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

APL; BIBR 1532; C Myc; HTERT; NB4; P21; Telomerase

Indexed keywords

ANTINEOPLASTIC AGENT; BIBR 1532; CASPASE 3; MESSENGER RNA; MYC PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL VIABILITY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION;

AMINOBENZOIC ACIDS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; NAPHTHALENES; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; RHO GTP-BINDING PROTEINS; TELOMERASE; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION;

EID: 84855926195     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2011.629378     Document Type: Article

References (33)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-70. (Pubitemid 30046295)
2. Kelland L. Targeting the limitless replicative potential of cancer: the telomerase/telomere pathway. Clin Cancer Res 2007;13(17):4960-4963. (Pubitemid 47502059)
3. Mason M, Schuller A, Skordalakes E. Telomerase structure function. Curr Opin Struct Biol 2011;21(1):92-100.
4. Wojtyla A, Gladych M, Rubis B. Human telomerase activity regulation. Mol Biol Rep 2011;38(5):3339-3349.
5. Cerni C. Telomeres, telomerase, and myc. An update. Mutat Res 6. 2000;462(1):31-47.
6. Wang Z, Kyo S, Takakura M, Tanaka M, Yatabe N, Maida Y, Fujiwara M, Hayakawa J, Ohmichi M, Koike K, Inoue M. Progesterone regulates human telomerase reverse transcriptase gene expression via activation of mitogen-activated protein kinase signaling pathway. Cancer Res 2000;60(19):5376-5381.
7. Henderson YC, Breau RL, Liu TJ, Clayman GL. Telomerase activity in head and neck tumors after introduction of wild-type p53, p21, p16, and E2F-1 genes by means of recombinant adenovirus. Head Neck 2000;22(4):347-354. (Pubitemid 30413299)
8. Chen H, Li Y, Tollefsbol TO. Strategies targeting telomerase inhibition. Mol Biotechnol 2009;41(2):194-199.
9. Feldser DM, Hackett JA, Greider CW. Telomere dysfunction and the initiation of genome instability. Nat Rev Cancer 2003;3(8):623-627
10. Blackburn EH. Telomere states and cell fates. Nature 2000;408(6808):53- 56.
11. Röth A, Dürig J, Himmelreich H, Bug S, Siebert R, Dührsen U, Lansdorp PM, Baerlocher GM. Short telomeres and high telomerase activity in T-cell prolymphocytic leukemia. Leukemia 2007;21(12):2456- 2462 (Pubitemid 350148888)
12. Ghaffari SH, Shayan-Asl N, Jamialahmadi AH, Alimoghaddam K, Ghavamzadeh A. Telomerase activity and telomere length in patients with acute promyelocytic leukemia: indicative of proliferative activity, disease progression, and overall survival. Ann Oncol 2008;19(11):1927-1934.
13. Damm K, Hemmann U, Garin-Chesa P, Hauel N, Kauffmann I, Priepke H, Niestroj C, Daiber C, Enenkel B, Guilliard B, Lauritsch I, Müller E, Pascolo E, Sauter G, Pantic M, Martens UM, Wenz C, Lingner J, Kraut N, Rettig WJ, Schnapp A. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J 2001;20(24):6958-6968. (Pubitemid 34062288)
14. Pascolo E, Wenz C, Lingner J, Hauel N, Priepke H, Kauffmann I, Garin-Chesa P, Rettig WJ, Damm K, Schnapp A. Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J Biol Chem 2002;277(18):15566-15572. (Pubitemid 34967825)
15. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009;9 (6):400-414.
16. El-Daly H, Kull M, Zimmermann S, Pantic M, Waller CF, Martens UM. Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. Blood 2005;105(4):1742-1749. (Pubitemid 40223698)
17. Raff MC. Social controls on cell survival and cell death. Nature 1992;356(6368):397-400.
18. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002;2(9):647-656 (Pubitemid 37328916)
19. Direct Short-Term Cytotoxic Effects of BIBR 1532 on Acute Promyelocytic Leukemia ... Page 11 of 17 http://informahealthcare.com/doi/full/10.3109/ 07357907.2011.629378 1/14/2012
20. Ducrest AL, Amacker M, Mathieu YD, Cuthbert AP, Trott DA, Newbold RF, Nabholz M, Lingner J. Regulation of human telomerase activity: repression by normal chromosome 3 abolishes nuclear telomerase reverse transcriptase transcripts but does not affect c-Myc activity. Cancer Res 2001;61 (20):7594-7602. (Pubitemid 32995053)
21. Kang KH, Kim WH, Choi KH. p21 promotes ceramide-induced apoptosis and antagonizes the antideath effect of Bcl-2 in human hepatocarcinoma cells. Exp Cell Res 1999;253(2):403-412. (Pubitemid 30003101)
22. John K, Alla V, Meier C, Pützer BM. GRAMD4 mimics p53 and mediates the apoptotic function of p73 at mitochondria. Cell Death Differ 2011;18(5):874-886.
23. Melino G, Bernassola F, Ranalli M, Yee K, Zong WX, Corazzari M, Knight RA, Green DR, Thompson C, Vousden KH. p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. J Biol Chem 2004;279(9):8076-8083 (Pubitemid 38294697)
24. Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer 24. 2008;8(3):167-179. (Pubitemid 351305939)
25. Shay JW. Meeting report: the role of telomeres and telomerase in cancer. Cancer Res 2005;65(9):3513-3517. (Pubitemid 40616321)
26. Shay JW, Wright WE. Telomerase therapeutics for cancer: challenges and new directions. Nat Rev Drug Discov 2006;5(7):577-584. (Pubitemid 43971192)
27. Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A, Beijersbergen RL, Knoll JH, Meyerson M, Weinberg RA. Inhibition of telomerase limits the growth of human cancer cells. Nat Med 1999;5(10):1164-1170 (Pubitemid 29474421)
28. Folini M, Brambilla C, Villa R, Gandellini P, Vignati S, Paduano F, Daidone MG, Zaffaroni N. Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells. Eur J Cancer 2005;41 (4):624-634. (Pubitemid 40292743)
29. Tabori U, Wong V, Ma J, Shago M, Alon N, Rutka J, Bouffet E, Bartels U, Malkin D, Hawkins C. Telomere maintenance and dysfunction predict recurrence in paediatric ependymoma. Br J Cancer 2008;99(7):1129-1135.
30. Ghanem L, Steinman R. A proapoptotic function of p21 in differentiating granulocytes. Leuk Res 2005;29 (11):1315-1323 (Pubitemid 41297644)
31. Qiao L, McKinstry R, Gupta S, Gilfor D, Windle JJ, Hylemon PB, Grant S, Fisher PB, Dent P. Cyclin kinase inhibitor p21 potentiates bile acid-induced apoptosis in hepatocytes that is dependent on p53. Hepatology 2002;36(1):39-48. (Pubitemid 34700760)
32. Wang X, Gao P, Long M, Lin F, Wei JX, Ren JH, Yan L, He T, Han Y, Zhang HZ. Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol 2010.
33. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007;35(4):495-516. (Pubitemid 46911891)